Last 12 months
Inside the activity.
2 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2024 Filed Mar 1, 2024 16:22 UTC |
DiMarco KathrynCorporate Controller
|
Exercise / conversionRestricted Stock Units · Derivative | 4,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000007 · wk-form4_1709328168.xml · derivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,957 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:22 UTC |
DiMarco KathrynCorporate Controller
|
Tax withholdingCommon Stock | 1,868 | $18.04 | $33,698.72 |
DisclosureSEC source: 0001821825-24-000007 · wk-form4_1709328168.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,737 Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:22 UTC |
DiMarco KathrynCorporate Controller
|
Exercise / conversionCommon Stock | 4,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001821825-24-000007 · wk-form4_1709328168.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:24 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 33,044 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000011 · wk-form4_1709328243.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,044 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:24 UTC |
WALSH MATTHEW MChief Financial Officer
|
Tax withholdingCommon Stock | 11,393 | $18.04 | $205,529.72 |
DisclosureSEC source: 0001821825-24-000011 · wk-form4_1709328243.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,062 Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:24 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionCommon Stock | 33,044 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001821825-24-000011 · wk-form4_1709328243.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:24 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 12,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000012 · wk-form4_1709328256.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,117 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:24 UTC |
Stahler Rachel AChief Information Officer
|
Tax withholdingCommon Stock | 4,326 | $18.04 | $78,041.04 |
DisclosureSEC source: 0001821825-24-000012 · wk-form4_1709328256.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,572 Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:24 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionCommon Stock | 12,117 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001821825-24-000012 · wk-form4_1709328256.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:24 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionRestricted Stock Units · Derivative | 8,261 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000010 · wk-form4_1709328214.xml · derivative · entry 3 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,261 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:24 UTC |
Nisita VittorioHead of Global Business Svcs
|
Tax withholdingCommon Stock | 3,038 | $18.04 | $54,805.52 |
DisclosureSEC source: 0001821825-24-000010 · wk-form4_1709328214.xml · nonDerivative · entry 2 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,109 Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:24 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionCommon Stock | 8,261 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001821825-24-000010 · wk-form4_1709328214.xml · nonDerivative · entry 1 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:23 UTC |
Ali KevinDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 88,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000009 · wk-form4_1709328202.xml · derivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 88,121 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:23 UTC |
Ali KevinDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 40,414 | $18.04 | $729,068.56 |
DisclosureSEC source: 0001821825-24-000009 · wk-form4_1709328202.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,326 Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:23 UTC |
Ali KevinDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 88,121 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001821825-24-000009 · wk-form4_1709328202.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:23 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Exercise / conversionRestricted Stock Units · Derivative | 14,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000008 · wk-form4_1709328178.xml · derivative · entry 3 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,319 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:23 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Tax withholdingCommon Stock | 4,223 | $18.04 | $76,182.92 |
DisclosureSEC source: 0001821825-24-000008 · wk-form4_1709328178.xml · nonDerivative · entry 2 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,112 Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:23 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Exercise / conversionCommon Stock | 14,319 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001821825-24-000008 · wk-form4_1709328178.xml · nonDerivative · entry 1 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:22 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 11,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000005 · wk-form4_1709328144.xml · derivative · entry 3 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,015 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:22 UTC |
Falcione AaronChief Human Resources Officer
|
Tax withholdingCommon Stock | 3,960 | $18.04 | $71,438.40 |
DisclosureSEC source: 0001821825-24-000005 · wk-form4_1709328144.xml · nonDerivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,817 Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:22 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionCommon Stock | 11,015 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001821825-24-000005 · wk-form4_1709328144.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 11:46 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
PurchaseCommon Stock | 2,720 | $18.36 | $49,938.93 |
DisclosureSEC source: 0001821825-24-000002 · wk-form4_1708706810.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,181 Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 16:16 UTC |
DiMarco KathrynCorporate Controller
|
Exercise / conversionRestricted Stock Units · Derivative | 1,871 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003170 · doc4.xml · derivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,871 shares Expires 2024-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On each of February 9, 2022, February 9, 2023, and February 9, 2024, one-third of the RSUs vested. F2 · derivative.expiration_date: On each of February 9, 2022, February 9, 2023, and February 9, 2024, one-third of the RSUs vested. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 16:16 UTC |
DiMarco KathrynCorporate Controller
|
Tax withholdingCommon Stock | 740 | $16.31 | $12,069.40 |
DisclosureSEC source: 0001209191-24-003170 · doc4.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,648 Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 16:16 UTC |
DiMarco KathrynCorporate Controller
|
Exercise / conversionCommon Stock | 1,871 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003170 · doc4.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 22:07 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 22,347 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045067 · doc4.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,347 shares Expires 2023-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On each of August 5, 2021, August 5, 2022 and August 5, 2023, one-third of the RSUs vested. F2 · derivative.expiration_date: On each of August 5, 2021, August 5, 2022 and August 5, 2023, one-third of the RSUs vested. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 22:07 UTC |
WALSH MATTHEW MChief Financial Officer
|
Tax withholdingCommon Stock | 11,006 | $21.53 | $236,959.18 |
DisclosureSEC source: 0001209191-23-045067 · doc4.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,411 Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 22:07 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionCommon Stock | 22,347 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045067 · doc4.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 18:07 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 12,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045068 · doc4.xml · derivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,895 shares Expires 2023-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On each of August 5, 2021, August 5, 2022 and August 5, 2023, one-third of the RSUs vested. F2 · derivative.expiration_date: On each of August 5, 2021, August 5, 2022 and August 5, 2023, one-third of the RSUs vested. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 18:07 UTC |
Stahler Rachel AChief Information Officer
|
Tax withholdingCommon Stock | 4,418 | $21.53 | $95,119.54 |
DisclosureSEC source: 0001209191-23-045068 · doc4.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,781 Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 18:07 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionCommon Stock | 12,895 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045068 · doc4.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:57 UTC |
Ozuah PhilipDirector
|
GrantPhantom Stock · Derivative | 10,086 | $19.83 | $200,005.38 |
DisclosureSEC source: 0001209191-23-036791 · doc4.xml · derivative · entry 1 Ozuah Philip · CIK 0001859685 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,285 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:54 UTC |
LAZARUS ROCHELLE BDirector
|
GrantPhantom Stock · Derivative | 10,086 | $19.83 | $200,005.38 |
DisclosureSEC source: 0001209191-23-036779 · doc4.xml · derivative · entry 3 LAZARUS ROCHELLE B · CIK 0001082206 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,285 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:46 UTC |
COX CARRIE SMITHDirector
|
GrantPhantom Stock · Derivative | 10,086 | $19.83 | $200,005.38 |
DisclosureSEC source: 0001209191-23-036752 · doc4.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,232 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:51 UTC |
Ezekowitz AlanDirector
|
GrantPhantom Stock · Derivative | 10,086 | $19.83 | $200,005.38 |
DisclosureSEC source: 0001209191-23-036769 · doc4.xml · derivative · entry 1 Ezekowitz Alan · CIK 0001780209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,285 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:53 UTC |
Gayle Helene DDirector
|
GrantPhantom Stock · Derivative | 10,086 | $19.83 | $200,005.38 |
DisclosureSEC source: 0001209191-23-036774 · doc4.xml · derivative · entry 1 Gayle Helene D · CIK 0001487047 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,285 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:48 UTC |
ESSNER ROBERTDirector
|
GrantPhantom Stock · Derivative | 10,086 | $19.83 | $200,005.38 |
DisclosureSEC source: 0001209191-23-036761 · doc4.xml · derivative · entry 1 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,285 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 21:00 UTC |
Sharp ShaliniDirector
|
GrantPhantom Stock · Derivative | 10,086 | $19.83 | $200,005.38 |
DisclosureSEC source: 0001209191-23-036798 · doc4.xml · derivative · entry 2 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,594 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:58 UTC |
Patton Cynthia MDirector
|
GrantPhantom Stock · Derivative | 10,086 | $19.83 | $200,005.38 |
DisclosureSEC source: 0001209191-23-036793 · doc4.xml · derivative · entry 1 Patton Cynthia M · CIK 0001560565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,285 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 16:59 UTC |
Whiteford Grace PumaDirector
|
GrantPhantom Stock · Derivative | 10,086 | $19.83 | $200,005.38 |
DisclosureSEC source: 0001209191-23-036794 · doc4.xml · derivative · entry 2 Whiteford Grace Puma · CIK 0001706213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,285 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:52 UTC |
Francisco Ma. FatimaDirector
|
GrantPhantom Stock · Derivative | 10,086 | $19.83 | $200,005.38 |
DisclosureSEC source: 0001209191-23-036771 · doc4.xml · derivative · entry 2 Francisco Ma. Fatima · CIK 0001747222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,285 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:55 UTC |
McGarry Martha EDirector
|
GrantPhantom Stock · Derivative | 10,086 | $19.83 | $200,005.38 |
DisclosureSEC source: 0001209191-23-036787 · doc4.xml · derivative · entry 1 McGarry Martha E · CIK 0001859699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,285 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:54 UTC |
Leone Deborah RDirector
|
GrantPhantom Stock · Derivative | 10,086 | $19.83 | $200,005.38 |
DisclosureSEC source: 0001209191-23-036783 · doc4.xml · derivative · entry 2 Leone Deborah R · CIK 0001859703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,285 Underlying: Common Stock · 10,086 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 16, 2022, September 15, 2022, December 15, 2022 and March 16, 2023. Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:43 UTC |
Fiedler SusanneChief Commercial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 4,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028099 · doc4.xml · derivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,989 Underlying: Common Stock · 4,984 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.exercise_date: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.expiration_date: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:43 UTC |
Fiedler SusanneChief Commercial Officer
|
Tax withholdingCommon Stock | 1,588 | $24.24 | $38,493.12 |
DisclosureSEC source: 0001209191-23-028099 · doc4.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,191 Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:43 UTC |
Fiedler SusanneChief Commercial Officer
|
Exercise / conversionCommon Stock | 4,984 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-028099 · doc4.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:46 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Exercise / conversionRestricted Stock Units · Derivative | 1,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028106 · doc4.xml · derivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,248 Underlying: Common Stock · 1,246 shares Expires 2023-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:46 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Tax withholdingCommon Stock | 355 | $24.24 | $8,605.20 |
DisclosureSEC source: 0001209191-23-028106 · doc4.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,461 Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:46 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Exercise / conversionCommon Stock | 1,246 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-028106 · doc4.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:42 UTC |
DiMarco KathrynCorporate Controller
|
Exercise / conversionRestricted Stock Units · Derivative | 1,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028096 · doc4.xml · derivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,248 Underlying: Common Stock · 1,246 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.